Literature DB >> 10622563

Clinical significance of hepatitis C virus genotypes.

M U Mondelli1, E Silini.   

Abstract

The advent of genotyping assays has stimulated investigators around the world to study the molecular epidemiology of hepatitis C virus (HCV) infection in specific patient categories, as well as possible correlations with the clinical and histological features of chronic liver disease and response to antiviral treatment. While a general consensus has been reached on the worldwide epidemiology and distribution of HCV types in certain risk categories (i.e. intravenous drug users), the association between genotype 1b and severe liver disease is still controversial. Although generalized use of genotyping is not presently recommended for clinical or epidemiological monitoring, several studies emphasize to the importance of HCV genotyping as part of a therapeutic algorithm. This recommendation is based on overwhelming evidence in support of a correlation between genotype 1 and a poor response to interferon-a alone or in combination with ribavirin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622563     DOI: 10.1016/s0168-8278(99)80377-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

Review 1.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

2.  Hepatitis C-related arthropathy: Diagnostic and treatment considerations.

Authors:  Nyingi M Kemmer; Kenneth E Sherman
Journal:  J Musculoskelet Med       Date:  2010-09

Review 3.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Prevalence of hepatitis C virus (HCV) genotypes among positive UAE patients.

Authors:  Mubarak S Alfaresi
Journal:  Mol Biol Rep       Date:  2010-11-20       Impact factor: 2.316

5.  Risk factors for hepatocellular carcinoma in Turkey.

Authors:  O Uzunalimoğlu; C Yurdaydin; H Cetinkaya; H Bozkaya; T Sahin; S Colakoğlu; E Tankurt; M Sarioğlu; S Ozenirler; H Akkiz; N Tözün; H Değertekin; A Okten
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

6.  Amantadine therapy for chronic hepatitis C.

Authors:  Jill P Smith; Thomas R Riley; Attila Devenyi; Sandra I Bingaman; Allen Kunselman
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

7.  Hepatitis C virus (HCV) genotyping by annealing reverse transcription-PCR products with genotype-specific capture probes.

Authors:  Jungmin Rho; Jong Soon Ryu; Wonhee Hur; Chang Wook Kim; Jeong Won Jang; Si Hyun Bae; Jong Young Choi; Sung Key Jang; Seung Kew Yoon
Journal:  J Microbiol       Date:  2008-02       Impact factor: 3.422

8.  Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

Authors:  Diane Thibeault; Christiane Bousquet; Rock Gingras; Lisette Lagacé; Roger Maurice; Peter W White; Daniel Lamarre
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 9.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 10.  Overwhelming postsplenectomy infection syndrome in adults - a clinically preventable disease.

Authors:  Takehiro Okabayashi; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.